These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15266245)

  • 1. Conference report--at the forefront of cancer research: clinical results highlights of the annual meeting of the 95th American Association for Cancer Research, March 27-31, 2004; Orlando, Florida.
    Mariani SM
    MedGenMed; 2004 May; 6(2):19. PubMed ID: 15266245
    [No Abstract]   [Full Text] [Related]  

  • 2. Conference report--at the forefront of cancer research: preclinical data highlights of annual meeting of the 95th American Association for Cancer Research; March 27-31, 2004; Orlando, Florida.
    Mariani SM
    MedGenMed; 2004 May; 6(2):18. PubMed ID: 15266244
    [No Abstract]   [Full Text] [Related]  

  • 3. Highlights from the Eigth International Kidney Cancer Symposium.
    Hutson T
    Clin Adv Hematol Oncol; 2009 Dec; 7(12):796-8. PubMed ID: 20332749
    [No Abstract]   [Full Text] [Related]  

  • 4. Highlights in renal cell carcinoma from the 2012 American Society of Clinical Oncology Annual Meeting.
    Rini BI
    Clin Adv Hematol Oncol; 2012 Sep; 10(9 Suppl 15):1-24. PubMed ID: 23072938
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
    Gardner TA; Logan T
    J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946
    [No Abstract]   [Full Text] [Related]  

  • 6. What's new in renal cell carcinoma.
    Meng MV; Nelson H
    Bull Am Coll Surg; 2012 Aug; 97(8):65-6. PubMed ID: 22973751
    [No Abstract]   [Full Text] [Related]  

  • 7. Decade in review-kidney cancer: discoveries, therapies and opportunities.
    Linehan WM; Ricketts CJ
    Nat Rev Urol; 2014 Nov; 11(11):614-6. PubMed ID: 25287783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy.
    Kishida T; Yao M; Uemura H; Ohlmann C; Tomita Y; Bukowski RM; Naito S
    Int J Urol; 2010 Mar; 17(3):198-205. PubMed ID: 20409215
    [No Abstract]   [Full Text] [Related]  

  • 9. [Research impulses for personalized cancer therapies].
    Aktuelle Urol; 2013 Sep; 44(5):349. PubMed ID: 24043531
    [No Abstract]   [Full Text] [Related]  

  • 10. [Targeted therapy for renal cell carcinoma].
    Terai K; Horie S
    Nihon Jinzo Gakkai Shi; 2016; 58(4):568-72. PubMed ID: 27416700
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted for destruction: the molecular basis for development of novel therapeutic strategies in renal cell cancer.
    Srinivasan R; Linehan WM
    J Clin Oncol; 2005 Jan; 23(3):410-2. PubMed ID: 15572728
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma.
    Chapman AE; Goldstein LJ
    Semin Oncol; 1995 Feb; 22(1):17-28. PubMed ID: 7855615
    [No Abstract]   [Full Text] [Related]  

  • 13. The multidrug resistance gene in renal cell carcinoma.
    Klein EA
    Semin Urol; 1989 Nov; 7(4):207-14. PubMed ID: 2575783
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapeutic indication of interferons for renal cell carcinoma].
    Harano M; Naito S
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():647-51. PubMed ID: 16523970
    [No Abstract]   [Full Text] [Related]  

  • 15. Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma.
    Figlin RA; Alvin H; Meinhardt CL
    Urologe A; 2004 Sep; 43 Suppl 3():S144-5. PubMed ID: 15179554
    [No Abstract]   [Full Text] [Related]  

  • 16. [Molecular targeted therapy for renal cell carcinoma].
    Kakehi Y
    Rinsho Ketsueki; 2008 Aug; 49(8):622-5. PubMed ID: 18800611
    [No Abstract]   [Full Text] [Related]  

  • 17. Third-Line Treatment Options for Kidney Cancer.
    Posadas EM; Limvorasak S; Figlin RA
    Oncology (Williston Park); 2016 Sep; 30(9):813-5. PubMed ID: 27633411
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting SPOP with small molecules provides a novel strategy for kidney cancer therapy.
    Zheng T; Yang CG
    Sci China Life Sci; 2017 Jan; 60(1):91-93. PubMed ID: 27888385
    [No Abstract]   [Full Text] [Related]  

  • 19. Rational therapy for renal cell carcinoma based on its genetic targets.
    Messer J; Drabick J; Kaag M
    Adv Exp Med Biol; 2013; 779():291-308. PubMed ID: 23288645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular biology of renal cancer: bases for genetic directed therapy in advanced disease].
    Maroto Rey JP; Cillán Narvaez E
    Arch Esp Urol; 2013 Jun; 66(5):517-23. PubMed ID: 23793769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.